TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04773249

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lateral Epicondylitis Bandage
Description: The lateral epicondylitis bandage was first used by Ilfeld in 1965, and it is a non-elastic band that prevents the expansion of the muscles in the proximal forearm. A lateral epicondylitis bandage will be given to the patient for 6 weeks. The bandage will be positioned 5 cm distal to the lateral epicondyle to allow for elbow flexion. After the application, patients will be asked to punch and the belt on the band will be tightened. After the patients are asked to open the fist, the suitability of the pressure applied to the forearm will be evaluated. Patients will be asked to repeat this application while wearing the band. The patients will also be asked to use the bandage throughout the day, and to remove them during bathing and sleeping.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wrist Extension Splint
Description: Wrist extension splint is an upper extremity orthosis that keeps the wrist at 15-20 degrees of extension with the polyethylene bar it contains. A wrist extension splint will be given to the patient for 6 weeks. The splint will be used to keep the wrist at 15-20 degrees of extension and to wrap the distal wrist and forearm without hindering finger movements. The patients will be asked to use the splint throughout the day, and to remove them during bathing and sleeping.
Study: NCT04860843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block
Description: Participants will receive a thoracic paravertebral with local anesthetic infiltrate (30ml of 0.35% ropivacaine with 1:400K epinephrine).

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Thoracic paravertebral block
Description: Participants will receive a thoracic paravertebral with local anesthetic infiltrate (30ml of 0.35% ropivacaine with 1:400K epinephrine).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pecs block
Description: Participants will receive a pecs block with local anesthetic infiltrate (30ml of 0.25% ropivacaine with 1:400K epinephrine).
Study: NCT04874207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Dose adaptation at the beginning of cycle 2 and cycle 3 after regorafenib dosage at day 15
Study: NCT04860843

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham Pecs block
Description: Participants will receive a and a pecs block with saline infiltrate (30ml normal saline; 0.9% NaCl).
Study: NCT05157204

Intervention type: PROCEDURE
Intervention: measurment of interleukin-6 at exhaled condensate
Description: the breath condensate samples were collected using a specially designed condensing chamber ( Ecoscreen; Jaeger, Hoechberg, Germany) to measure the interleukin-6 at exhaled condensate of 60 participants
Study: NCT06557551

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thin catheter surfactant
Description: Surfactant given through thin catheter inserted under video laryngoscopy at or after 5 minutes of life
Study: NCT06491342

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Probiotic-Lactobacillus Zeae and Lactobacillus reuteri

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT05157204

Intervention type: PROCEDURE
Intervention: measurment of interleukin-6 at exhaled condensate
Description: the breath condensate samples were collected using a specially designed condensing chamber ( Ecoscreen; Jaeger, Hoechberg, Germany) to measure the interleukin-6 at exhaled condensate of 60 participants

Intervention type: PROCEDURE
Intervention: measurment of interleukin-6 at exhaled condensate
Description: the breath condensate samples were collected using a specially designed condensing chamber ( Ecoscreen; Jaeger, Hoechberg, Germany) to measure the interleukin-6 at exhaled condensate of 60 participants
Study: NCT05777005

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 5A's/5R's advice
Description: 5A's (Ask, Advise, Assess, Assist, Arrange) for smokers who are ready to quit, and 5R's (relevance, risks, rewards, roadblocks, and repetition) for smokers who are not ready to quit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5A's/5R's advice
Description: 5A's (Ask, Advise, Assess, Assist, Arrange) for smokers who are ready to quit, and 5R's (relevance, risks, rewards, roadblocks, and repetition) for smokers who are not ready to quit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brief leaflet on health warning and smoking cessation
Description: The contents of the leaflet include the absolute risk of smoking, diseases caused by active and second-hand smoking, horrible pictorial warnings of the health consequences of active and second-hand smoking, and the benefits of quitting.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief leaflet on health warning and smoking cessation
Description: The contents of the leaflet include the absolute risk of smoking, diseases caused by active and second-hand smoking, horrible pictorial warnings of the health consequences of active and second-hand smoking, and the benefits of quitting.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-help smoking cessation booklet
Description: The contents include information about the benefits of quitting, methods to quit, how to handle withdrawal symptoms, misperceptions of quitting, etc.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-help smoking cessation booklet
Description: The contents include information about the benefits of quitting, methods to quit, how to handle withdrawal symptoms, misperceptions of quitting, etc.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counselor-led individual support
Description: Participants will receive three months of counselor-led individual support via WeChat. The regular messages and instant messaging on psychosocial support aim to provide cessation advice, increase self-efficacy and confidence, and social support and behavioral capacity of quitting.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Chatbot-led group support
Description: Participants will receive three months of chatbot-led group support via WeChat.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chatbot-led group support
Description: Participants will receive three months of chatbot-led group support via WeChat.
Study: NCT05733585

Intervention type: DEVICE
Intervention: Purabond
Description: hemostatic efficacy of PuraBond
Study: NCT05701384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: 160mg po qd
Study: NCT05781490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumentin® 44 Powder for oral foam
Description: Lumentin® 44 is a foam for oral use.
Study: NCT05721339

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: ACT will be applied through 8 sessions by the psychological flexibility processes, which were grouped into three response styles: open, aware, and active. Openness is reflected by acceptance, which means the conscious embrace of psychological events without unnecessary attempts to change their frequency. Defusion means untangling unhelpful thoughts and responding to mental experiences as experiences rather than guides to action. The awareness set, which is reflected by applying self-as-context, which means a continuous and secure I from which events are experienced but distinct from those events. A present moment means ongoing, nonjudgmental contact with internal and external events as they occur in the present moment. The active set, which was reflected by making the intern nurses embrace their desired and chosen life values directions, and commit action to selected values.
Study: NCT05209074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Description: Ivosidenibflat dose (250mgor 500mg) daily on day 1 of a 14 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Description: mFOLFIRINOX on days 1-3 of a 14-day cycle. Surgical resection after up to ninety (90) days of treatment.
Study: NCT06229080

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NexGel
Description: When a planned perfused area includes two or more Couinaud segments and more than 50% of the target area is non-tumorous liver, short-acting gelatin sponge particles (NexGel) will be administered to the hepatic arteries toward the non-tumorous liver. The embolization particles will be prepared by mixing one vial of the particles with 5 mL of iodinated contrast agents and intra-arterially delivered with a microcatheter 2.0-Fr or larger. After confirming the disappearance or substantial reduction of liver parenchymal staining of the embolized area on angiography, radioembolization using Y90 glass or resin microspheres will be conducted. Digital subtraction angiography will be performed 30 minutes after the transient embolization to identify recanalization of the transiently embolized hepatic arteries.
Study: NCT06561555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48
Description: RC48 at a dosage of 2mg/kg administered intravenously every 3 weeks (ivgtt q3w) is continued until disease progression, with the allowance for treatment discontinuation due to disease progression, death, intolerable toxicity, withdrawal of informed consent, initiation of new antineoplastic therapy, or other reasons specified in the protocol, with the earliest occurring event taking precedence. Alternatively, the study investigator may determine the need to discontinue treatment.
Study: NCT04995003

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: T cells or CAR T cells
Description: There are 2 dose levels:~Dose Level 1 (1x10\^8 cells/m2) and Dose Level -1 (5x10\^7 cells/m2). In the event that Dose Level 1 is not tolerable, de-escalation to Dose Level -1 will occur.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: T cells or CAR T cells
Description: There are 2 dose levels:~Dose Level 1 (1x10\^8 cells/m2) and Dose Level -1 (5x10\^7 cells/m2). In the event that Dose Level 1 is not tolerable, de-escalation to Dose Level -1 will occur.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injectable Product
Description: 2 mg/kg/dose (max 200 mg/dose) every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injectable Product
Description: 3 mg/kg/dose (\<40kg) or 124 mg (≥40 kg) every 2 weeks
Study: NCT06147401

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PENG plus LFCN block
Description: The experimental arm will be subjected to a combination of peripheral blocks: the interfascial block of the PENG and the perinervous block of the LFCN~The PENG block involves deposition of local anesthetic in the fascial plane between the psoas muscle and the superior pubic ramus.~The LFCN block consists of applying local anesthetic near the nerve. The LFCN lies in the subcutaneous plane deep to the fascia lata below the anterior superior ischiatic spine.
Study: NCT06208163

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chiropractic
Description: Chiropractic spinal adjustments
Study: NCT05452512

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self monitoring
Description: Self monitoring using smart clinical trial application

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Self monitoring
Description: Self monitoring using smart clinical trial application

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smart watch assisted monitoring
Description: Smart watch-assisted adherence monitoring
Study: NCT06438367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]TGRX-326
Description: Healthy subjects will be given TGRX-326 60 mg orally on day 1.
Study: NCT05452512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D self-administration for 3 months

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D self-administration for 3 months
Study: NCT05295290

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cardiac Imaging
Description: ECG, echocardiogram, ambulatory monitor, exercise stress test

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cardiac Imaging
Description: ECG, echocardiogram, ambulatory monitor, exercise stress test
Study: NCT04347759

Intervention type: OTHER
Group type: OTHER
Intervention: Symptom Care at Home-Heart Failure
Description: When participants call, the IVR system will ask them about each of the selected symptoms, and the patient will report symptom presence and severity numerically with the touchtone keypad. Based on symptom severity, intervention group will receive automated coaching messages. There will be a toll-free number for participants to call and a password to log into the system which will be stored on a secure and HIPPA-compliant sever. Calls can be personalized to allow the voice to greet the patient by name.
Study: NCT05456841

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empathic Communication Skills (ECS) training
Description: The overall training goal of this 2.25 hour module ECS module is to enhance OCP recognition and responsiveness to lung cancer patients' empathic opportunities by communicating understanding, alleviating stigma and distress, and providing support. The ECS training also provides tools to OCPs to buffer/inoculate patients against stigmatizing attitudes and behaviors by others such that lung cancer patients who currently or formerly smoked can be given small doses of an opposing viewpoint (termed as preparing patients for recurring smoking questions) and suggestions of counterarguments in order to make them resistant to future stigmatizing attacks by others

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empathic Communication Skills (ECS) training
Description: The overall training goal of this 2.25 hour module ECS module is to enhance OCP recognition and responsiveness to lung cancer patients' empathic opportunities by communicating understanding, alleviating stigma and distress, and providing support. The ECS training also provides tools to OCPs to buffer/inoculate patients against stigmatizing attitudes and behaviors by others such that lung cancer patients who currently or formerly smoked can be given small doses of an opposing viewpoint (termed as preparing patients for recurring smoking questions) and suggestions of counterarguments in order to make them resistant to future stigmatizing attacks by others

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care participant interaction
Description: Standard of Care participant interaction

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care participant interaction
Description: Standard of Care participant interaction
Study: NCT05376306

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Reduction: MBSR
Description: Four activities, one each week - raising body awareness, sitting meditation, mindful yoga, expanding awareness meditation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Reduction: MBSR
Description: Four activities, one each week - raising body awareness, sitting meditation, mindful yoga, expanding awareness meditation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Reduction : PMR
Description: Progressively tensing and releasing each muscle group from head to toe in a specific order.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Reduction : PMR
Description: Progressively tensing and releasing each muscle group from head to toe in a specific order.
Study: NCT05298501

Intervention type: OTHER
Intervention: No intervention/exposure
Description: No interventions/exposures will be administered or evaluated

Intervention type: OTHER
Intervention: No intervention/exposure
Description: No interventions/exposures will be administered or evaluated

Intervention type: OTHER
Intervention: No intervention/exposure
Description: No interventions/exposures will be administered or evaluated
Study: NCT05386836

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse oximeter validation population
Description: Evaluation of the SpO2 accuracy performance of the Sunrise Sensor 2 placed at the tip of the chin during non-motion conditions over the range of 70-100% by comparison to SaO2 values determined from arterial blood sample specimen analyzed by a CO-oximeter.
Study: NCT05897554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intra-arterial alteplase
Description: For patients in the successful MT plus intra-arterial alteplase group, after successful recanalization, neurointerventionalists administered intra-arterial thrombolysis with alteplase according to protocol. The angiographic scores will be assessed immediately after intra-arterial thrombolysis.
Study: NCT05311410

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-bloody dental procedures (control group)
Description: Control group composed of 30 positive patients for SARS-CoV-2, from the same ICU, submitted to non-bloody procedures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bloody dental procedures (study group)
Description: Study group consisting of 30 patients who require open dental treatment and with a positive PCR test for SARS-CoV-2 prior and admitted to the Intensive Care Unit.
Study: NCT05359757

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Effect of Naturalistic Teaching Strategies in Children with autism spectrum disorder
Description: In this group, the patients will be provided with both the naturalistic therapeutic techniques the PECS Therapy.~A baseline of the kids in this group will be made using the portage guide and PECS~* Incidental teaching trial, natural language paradigm, and time delay concepts will be incorporated in the therapy sessions and communication using picture cards will be made.~* 40 minutes session will be conducted in which 20 minutes session will be for naturalistic teaching techniques and 20 minutes will be for PECS.~* This will be followed for 30 sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PECS Therapy only
Description: A baseline will be developed using the portage guide and PECS.~* Communication strategies using the PECS picture cards will be made~* 30 minutes session will be conducted~* This will be followed for 30 sessions
Study: NCT05506137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine
Description: study whether topical pilocarpine drops induce a clinically significant improvement in xerostomia

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: study whether topical pilocarpine drops induce a clinically significant improvement in xerostomia
Study: NCT06050603

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: The target locations of TMS will be cortical regions defined by either anatomical landmarks or functional regions derived from the individual's functional and structural MRI for Aim 1. TMS target locations for Aim 2 and 3 are determined by Aim 1's results. These TMS target regions will be guided by a navigation system.~TMS will be parametrically varied with combinations of pulse strength and frequencies based on experimental conditions. TMS strength will be referred to the resting motor threshold (rMT), which will be determined independently for each participant. TMS pulses will be delivered at fixed time instants for Aim 2 and at time instants based on the phase of oscillatory neural activity for Aim 3.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: The target locations of TMS will be cortical regions defined by either anatomical landmarks or functional regions derived from the individual's functional and structural MRI for Aim 1. TMS target locations for Aim 2 and 3 are determined by Aim 1's results. These TMS target regions will be guided by a navigation system.~TMS will be parametrically varied with combinations of pulse strength and frequencies based on experimental conditions. TMS strength will be referred to the resting motor threshold (rMT), which will be determined independently for each participant. TMS pulses will be delivered at fixed time instants for Aim 2 and at time instants based on the phase of oscillatory neural activity for Aim 3.
Study: NCT05359757

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PECS Therapy only
Description: A baseline will be developed using the portage guide and PECS.~* Communication strategies using the PECS picture cards will be made~* 30 minutes session will be conducted~* This will be followed for 30 sessions
Study: NCT04209842

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: gastric balloon
Description: non surgical weight loss via placement of gastric balloon
Study: NCT04841876

Intervention type: OTHER
Intervention: rugby matches
Description: standard rugby-7s match
Study: NCT04954443

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Removing urinary catheter
Description: Removing urinary catheter after vaginal surgery of pelvic organ prolapse

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Removing urinary catheter
Description: Removing urinary catheter after vaginal surgery of pelvic organ prolapse
Study: NCT06147401

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FIC Block
Description: The control arm will be subjected to an interfascial block, the fascia iliaca Compartment Block.~The FICB consists in the injection of anaesthetic agents into the fascia iliaca compartment.
Study: NCT04867278

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: External Beam Radiation (XRT)
Description: Patients that undergo surgical fixation of an acetabular fracture will receive debridement and a single fraction of external beam radiotherapy to the surgical site within 72 hours of surgery.
Study: NCT04796220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine (900 mg/m2) will be administered intravenously on day 1.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused Ultrasound
Description: Focused ultrasound will be applied to up to 2 breast lesions on day 8.
Study: NCT05882721

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sofwave
Description: The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.~Other Names:~SUPERB
Study: NCT04796220

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Focused Ultrasound
Description: Gemcitabine (900 mg/m2) will be administered intravenously on day 1.Focused ultrasound will be applied to up to 2 breast lesions on day 8.
Study: NCT04867278

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Debridement
Description: Gluteus minimus debridement in the OR

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Debridement
Description: Gluteus minimus debridement in the OR
Study: NCT05622201

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Infusion